Roche's Q1 MDx Sales Drop 3 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Roche today reported that its sales for its molecular diagnostics products fell 3 percent for the first quarter as revenues for its Diagnostics Division overall grew 1 percent.

The Swiss diagnostics, pharmaceuticals, and research products firm reported total group sales of CHF 11.59 billion ($12.45 billion), up 5 percent year over year, and driven by its pharmaceutical products sales, which rose 6 percent to CHF 9.17 billion from CHF 8.62 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.